Lawyer Monthly Magazine - February 2020 Edition

72 WWW.LAWYER-MONTHLY.COM | FEB 2020 Transactions Reports This announcement appears as a matter of record only Deutsche Beteiligungs’ Acquisition of Majority Stake in Cartonplast Group Legal advisers to Deutsche Beteiligungs AG: Deutsche Beteiligungs' Acquisition of Majority Stake in Cartonplast Group Deutsche Beteiligungs AG (DBAG), a German-based listed private equity company, and DBAG-advised DBAG Fund VII entered into a share purchase agreement on 22 August 2019 for the acquisition of a majority stake in Cartonplast Group, the leading European operator of a pool system for reusable plastic layers used mainly for the transportation of glass containers in the food and beverage industry, from London-based financial investor Stirling Square Capital Partners. Shearman & Sterling acted as global counsel to Deutsche Beteiligungs AG and DBAG Fund VII on the acquisition, while Paksoy advised on the Turkish aspects with a team led by Stéphanie Beghe Sönmez (Partner) together with Miray Cura (Associate). Latham & Watkins acted as global counsel to Stirling Square Capital, with the Ozbek Attorney Partnership acting as local counsel, as well as, reportedly, J&A Garrigues, Pinheiro Neto Advogados, and Noerr Biedecki. ImCheck Therapeutics’ 48 million Fundraising ImCheck Therapeutics finalised its Series B fundraising for a total amount of €48 million, enabling them to advance its clinical pipeline of antibodies targeting gamma delta T cells against cancer and autoimmune diseases; Dechert, Dentons and Plasseraud IP advised as part of the operation. Dechertadvisednew investors(includingInnoBio,BpifranceParticipations, Capital Agent, Wellington Partners Venture Capital and Alexandria Venture Investments); Dentons advised the Marseille biotechnology company, Imcheck Therapeutics, its founders and historical investors (Boehringer Ingelheim Venture Fund (BIVF), Kurma Partners, Idinvest, Gimv and LSP); and, Alexandra Carrel from Cabinet Carrel and Denis Bourgarel CPI from Plasseraud IP advised ImCheck on intellectual property aspects. This announcement appears as a matter of record only ImCheck Therapeutics’ 48 Million Fundraising Intellectual property advisers to ImCheck: Legal adviser to InnoBio: Legal adviser to Marseille Biotechnology Company: